Looking for Partners for the HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage call

Short summary The company is preparing a proposal for the HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage: Personalised prevention of non- communicable diseases - addressing areas of unmet needs using multiple data sources call for prevention of cardiovascular disease in people with a health condition and/or mental health comorbidities using tailored-online interventions on lifestyle and emotion regulation. They are looking for partners for their consortium.

Full description Non-communicable diseases (NCDs) like cardiovascular diseases, diabetes, chronic respiratory diseases, mental disorders, neurological disorders, or cancer account for the 80% of the disease burden in EU countries. In addition to human costs of the diseases, the financial burden caused by these diseases are quite high and it is estimated that disease prevention can reduce it by 70% Among the abovementioned diseases, mental health problems affect 84 million people in EU where almost one in two young Europeans report unmet needs for mental health care . In addition to personal suffering, costs of mental health problems are estimated more than 4% of GDP (more than EU 600 billion) across the 27 EU countries and the United Kingdom . And comorbidity of mental diseases with physical diseases are quite common. For example, people who suffer from anxiety, depression or stress increase the risk due to the incorporation of a lifestyle that is not suitable for preventing cardiovascular disease and other medical conditions such as Irritable Bowel Syndrome (IBS). Affective or anxiety disorders are highly prevalent among people at high risk to develop psychosis and in many cases, are the main cause of dysfunctionality. Often, they have difficulties in engaging with mental health services being this situation an important obstacle to receiving appropriate treatment. Similarly, severe depression, schizophrenia and psychotic disorders are considered cardiovascular risk factors, independent of traditional risk factors for cardiovascular events. In addition to those, the effects of psychoactive drugs on the cardiovascular level should not be underestimated as well. Drug interaction is a concern when treating patients with cardiovascular risk who are taking psychotropic drugs, also with IBS. Approximately 10% of adults in EU are affected by the Irritable Bowel syndrome (IBS) which is a condition that affects stomach and intestines with symptoms of cramping, abdominal pain, bloating, gas, diarrhea or constipation or both. Even though IBS is not a life threatening condition, it affects the quality of life of patients profoundly. Absences of patients with IBS from work or education is recorded up to 13 days/ year and the costs of managing and treating this condition in Germany is estimated to be more than 2,3 Billion per year . The limited availability of therapists skilled in applying psychological therapy to gastrointestinal problems, the high costs of delivering the treatment, and the practical difficulties for patients of scheduling weekly visits at a clinic may limit widespread use and suggest that these strategies are reserved for later lines of therapy and an alternative method for preventing and managing the disease is required to reduce the burden. Reduction on cardiovascular events and IBS can be achieved by addressing three lifestyle aspects: a high-quality dietary pattern, physical activity and motivational behaviour changes. Therefore with this project we aim to develop a digital personalised evidence based intervention to tackle cardiovascular disease and mental health disease associated to medical conditions of high risk such as psychosis and irritable bowel syndrome, tailored to level of severity using AI to stratify the risk.

Advantages and innovations Developing personalized prevention according to stratified groups

Technical Specification or Expertise Sought · Hospitals, partners with clinical settings which can run pilot interventions with individuals of high risk of cardiovascular diseases such as patients with prescription of antipsychotic and antidepressants, or individuals at high risk of depression and anxiety such as patients having symptoms of irritable bowel syndrome and early episodes of psychosis. Within the study there will be a year long intervention with a follow-up. · Partners who have expertise in legal issues of patient rights and artificial intelligence applications in healthcare. · A partner who is experienced in health technology assessment · Partner experienced in federated learning who will be willing to help the set up at the clinical nodes owning the data. This may include development of the communication protocols, local model training, aggregation, refinement, validation/testing, etc., as well as supporting other consortium members in their developments

Contact / source: NEXT EEN Widgets (europa.eu)